References
1. Kenyon AP, Tribe RM,
Nelson-Piercy C, Girling JC, Williamson C, Seed PT, et al. Pruritus in
pregnancy: a study of anatomical distribution and prevalence in relation
to the development of obstetric cholestasis. Obstet Med. 2010
Mar;3(1):25–9.
2. Ovadia C, Seed PT,
Sklavounos A, Geenes V, Di Ilio C, Chambers J, et al. Association of
adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with
biochemical markers: results of aggregate and individual patient data
meta-analyses. Lancet. 2019 Mar 2;393(10174):899–909.
3. Ridlon JM, Bajaj JS. The
human gut sterolbiome: bile acid-microbiome endocrine aspects and
therapeutics. Acta Pharm Sin B. 2015 Mar;5(2):99–105.
4. Saleh MM, Abdo KR. Short
communication: Consensus on the management of obstetric cholestasis:
National UK survey. BJOG. 2006 Nov 2;114(1):99–103.
5. Gurung V, Middleton P,
Milan SJ, Hague W, Thornton JG. Interventions for treating cholestasis
in pregnancy. Cochrane Database Syst Rev. 2013 Jun 24;(6):CD000493.
6. Chappell LC, Bell JL,
Smith A, Linsell L, Juszczak E, Dixon PH, et al. Ursodeoxycholic acid
versus placebo in women with intrahepatic cholestasis of pregnancy
(PITCHES): a randomised controlled trial. Lancet [Internet]. 2019
Aug 1; Available from:
http://dx.doi.org/10.1016/S0140-6736(19)31270-X
7. Chappell LC, Chambers J,
Dixon PH, Dorling J, Hunter R, Bell JL, et al. Ursodeoxycholic acid
versus placebo in the treatment of women with intrahepatic cholestasis
of pregnancy (ICP) to improve perinatal outcomes: protocol for a
randomised controlled trial (PITCHES). Trials. 2018 Nov 27;19(1):657.
8. Chappell LC, Gurung V,
Seed PT, Chambers J, Williamson C, Thornton JG, et al. Ursodeoxycholic
acid versus placebo, and early term delivery versus expectant
management, in women with intrahepatic cholestasis of pregnancy:
semifactorial randomised clinical trial. BMJ. 2012 Jun 13;344:e3799.
9. Glantz A, Marschall H-U,
Lammert F, Mattsson L-A. Intrahepatic cholestasis of pregnancy: a
randomized controlled trial comparing dexamethasone and ursodeoxycholic
acid. Hepatology. 2005 Dec;42(6):1399–405.
10. Abu-Hayyeh S, Ovadia C,
Lieu T, Jensen DD, Chambers J, Dixon PH, et al. Prognostic and
mechanistic potential of progesterone sulfates in intrahepatic
cholestasis of pregnancy and pruritus gravidarum. Hepatology. 2016
Apr;63(4):1287–98.
11. Kremer AE, Martens JJWW,
Kulik W, Ruëff F, Kuiper EMM, van Buuren HR, et al. Lysophosphatidic
acid is a potential mediator of cholestatic pruritus. Gastroenterology.
2010 Sep;139(3):1008–18, 1018.e1.
12. Dixon PH, Williamson C.
The molecular genetics of intrahepatic cholestasis of pregnancy. Obstet
Med. 2008 Dec;1(2):65–71.
13. Manna LB, Ovadia C,
Lövgren-Sandblom A, Chambers J, Begum S, Seed P, et al. Enzymatic
quantification of total serum bile acids as a monitoring strategy for
women with intrahepatic cholestasis of pregnancy receiving
ursodeoxycholic acid treatment: a cohort study. BJOG. 2019
Dec;126(13):1633–40.